Journal of magnetic resonance imaging : JMRI
-
J Magn Reson Imaging · Apr 2018
Intravoxel incoherent motion diffusion-weighted imaging in assessing bladder cancer invasiveness and cell proliferation.
Nonmuscle-invasive bladder cancer (NMIBC, Stage T1 or lower) is treated with transurethral resection (TUR), while muscle-invasive bladder cancer (MIBC, Stage T2 or more) requires neoadjuvant chemotherapy before radical cystectomy. Hence, preoperative differentiation is vital. ⋯ 1 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:1054-1060.
-
J Magn Reson Imaging · Apr 2018
Textural features of dynamic contrast-enhanced MRI derived model-free and model-based parameter maps in glioma grading.
Presurgical glioma grading by dynamic contrast-enhanced MRI (DCE-MRI) has unresolved issues. ⋯ 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1099-1111.
-
J Magn Reson Imaging · Apr 2018
Lung Cancer: Short-Term Reproducibility of Intravoxel Incoherent Motion Parameters and Apparent Diffusion Coefficient at 3T.
To prospectively evaluate the short-term reproducibility of intravoxel incoherent motion (IVIM) parameters and apparent diffusion coefficient (ADC) in lung cancer patients. ⋯ 1 Technical Efficacy Stage: 1 J. Magn. Reson. Imaging 2018;47:1003-1012.
-
J Magn Reson Imaging · Apr 2018
Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Active surveillance (AS) is an important treatment strategy for prostate cancer (PCa). Prostate Imaging-Reporting and Data System (PI-RADS) v2 has been addressed, but few studies have reported the value of PI-RADS v2 for assessing risk stratification in patients with PCa, especially on selecting potential candidates for AS. ⋯ 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1072-1079.
-
J Magn Reson Imaging · Apr 2018
Optimization of region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification.
Clinical trials utilizing proton density fat fraction (PDFF) as an imaging biomarker for hepatic steatosis have used a laborious region-of-interest (ROI) sampling strategy of placing an ROI in each hepatic segment. ⋯ 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:988-994.